LUGANO, Switzerland, July 1, 2016 /PRNewswire/ --
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that the Company has signed an agreement, with Vifor Pharma ("Vifor") for the promotion and distribution of Aloxi®, an anti-nausea therapeutic medicine used to help prevent symptoms of chemotherapy-induced nausea and vomiting (CINV), in Spain. The agreement will commence on 1 July 2016.
This agreement builds on the existing agreement with Vifor for the promotion and distribution of Akynzeo®, the oral fixed combination of netupitant and palonosetron, developed for the prevention of CINV, in Spain, France, Switzerland, Portugal and the Benelux region. Previously, Aloxi® was distributed by Italfarmaco in Spain, however, due to the portfolio synergies with Vifor in other European countries, the agreement will now terminate on 1 July 2016. Under the terms of the new agreement with Vifor, Helsinn retains rights to all clinical development, international regulatory activities and the manufacturing and supply of Aloxi®. Vifor will have exclusive rights to promotion and sales of Aloxi® in Spain.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: "We are pleased to be able to strengthen our existing relationship with Vifor, a valued and trusted partner, through this agreement in Spain. This agreement complements Helsinn's existing agreement with Vifor on Akynzeo® and we look forward to working closely on this new, expanding partnership."
About the Helsinn Group
Helsinn is a privately owned cancer supportive care pharmaceutical group with an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model working with long standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China, as well as a product presence in about 90 countries globally.
In 2016, our 40th anniversary year, you can meet representatives from Helsinn at:
- ChemOutsourcing Conference (Parsippany, New Jersey, 19-21 September)
- CPhI Worldwide (Barcelona, Spain, 4-6 October)
- ESMO Congress (Copenhagen, Denmark, 7-11 October)
- BioEurope (Köln, Germany, 4-6 November)
For more information, please visit http://www.helsinn.com.
About Vifor Pharma
Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group's income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
For more information about Vifor Pharma and its parent company Galenica, please visit http://www.viforpharma.com and http://www.galenica.com.
For more information, please contact:
Head of Communication & Press Office
SOURCE Helsinn Group